富含半胱氨酸的酸性分泌蛋白与原发性肝癌发生发展的关系

冯颖; 杨雪; 王宪波

doi:10.3969/j.issn.1001-5256.2018.02.045

富含半胱氨酸的酸性分泌蛋白与原发性肝癌发生发展的关系

DOI: 10.3969/j.issn.1001-5256.2018.02.045

首都医科大学附属北京地坛医院中西医结合一科

基金项目:

北京市自然科学基金青年基金项目(7184219)；北京市医院管理局临床医学发展专项经费资助(ZYLX201707);北京市医院管理局青年人才培养“青苗”计划基金资助(QML20151702)；

详细信息

中图分类号: R735.7
计量
- 文章访问数: 2489
- HTML全文浏览量: 54
- PDF下载量: 458
- 被引次数: 0
出版历程
- 出版日期: 2018-02-20

Research advances in secreted protein acidic and rich in cysteine in hepatocellular carcinoma

First Department of Integrated Traditional Chinese and Western Medicine

Research funding:

摘要

摘要:
原发性肝癌是临床常见的恶性肿瘤,富含半胱氨酸的酸性分泌蛋白在肝癌的发展与转移过程中发挥着非常重要的作用。介绍了富含半胱氨酸的酸性分泌蛋白的结构与生物学功能,分析了其在恶性肿瘤中的作用机制及其与肝癌发展、转移的关系,并对其在肝癌诊治中的应用价值进行了分析与展望。
- 肝肿瘤 /
- 胞间信号肽类和蛋白质类 /
- 肿瘤转移 /
- 综述
Abstract:
Primary liver cancer is a common malignant tumor in clinical practice, and secreted protein acidic and rich in cysteine (SPARC) plays a very important role in the progression and metastasis of liver cancer.This article introduces the structure and biological function of SPARC and analyzes its mechanism of action in malignant tumors and its association with the progression and metastasis of liver cancer, as well as the perspectives of its application in the diagnosis and treatment of liver cancer.
- liver neoplasms /
- intercellular signaling peptides and proteins /
- neoplasm metastasis /
- review

HTML全文

参考文献(45)

[1]MAGISTRI P, TARANTINO G, BALLARIN R, et al.The evolving role of local treatments for hcc in the third millennium[J].Anticancer Res, 2017, 37 (2) :389-401.

[2]DUTTA R, MAHATO RI.Recent advances in hepatocellular carcinoma therapy[J].Pharmacol Ther, 2017, 173:106-117.

[3]BREKKEN RA, SAGE EH.SPARC, a matricellular protein:at the crossroads of cell-matrix communication[J].Matrix Biol, 2001, 19 (8) :816-827.

[4]PELLAGATTI A, JADERSTEN M, FORSBLOM AM, et al.Lenalidomide inhibits the malignant clone and up-regulates the SPARC gene mapping to the commonly deleted region in 5q-syndrome patients[J].Proc Natl Acad Sci U S A, 2007, 104 (27) :11406-11411.

[5]TORRES-NUNEZ E, SUAREZ-BREGUA P, CAL L, et al.Molecular cloning and characterization of the matricellular protein Sparc/osteonectin in flatfish, Scophthalmus maximus, and its developmental stage-dependent transcriptional regulation during metamorphosis[J].Gene, 2015, 568 (2) :129-139.

[6]CHLENSKI A, COHN SL.Modulation of matrix remodeling by SPARC in neoplastic progression[J].Semin Cell Dev Biol, 2010, 21 (1) :55-65.

[7]SAID N.Roles of SPARC in urothelial carcinogenesis, progression and metastasis[J].Oncotarget, 2016, 7 (41) :67574-67585.

[8]RIVERA LB, BRADSHAW AD, BREKKEN RA.The regulatory function of SPARC in vascular biology[J].Cell Mol Life Sci, 2011, 68 (19) :3165-3173.

[9]BOYINENI J, TANPURE S, GNANAMONY M, et al.SPARC overexpression combined with radiation retards angiogenesis by suppressing VEGF-A via miR410 in human neuroblastoma cells[J].Int J Oncol, 2016, 49 (4) :1394-1406.

[10]LANE TF, SAGE EH.Functional mapping of SPARC:peptides from two distinct Ca+ (+) -binding sites modulate cell shape[J].J Cell Biol, 1990, 111 (6 Pt 2) :3065-3076.

[11]RAHMAN M, CHAN AP, TANG MJ, et al.Correction:a peptide of SPARC interferes with the interaction between Caspase8 and Bcl2to resensitize chemoresistant tumors and enhance their regression in vivo[J].PLo S One, 2015, 10 (4) :e0127226.

[12]CHLENSKI A, LIU S, BAKER LJ, et al.Neuroblastoma angiogenesis is inhibited with a folded synthetic molecule corresponding to the epidermal growth factor-like module of the follistatin domain of SPARC[J].Cancer Res, 2004, 64 (20) :7420-7425.

[13]FUNK SE, SAGE EH.The Ca2 (+) -binding glycoprotein SPARC modulates cell cycle progression in bovine aortic endothelial cells[J].Proc Natl Acad Sci U S A, 1991, 88 (7) :2648-2652.

[14]MAURER P, HOHENESTER E, ENGEL J.Extracellular calcium-binding proteins[J].Curr Opin Cell Biol, 1996, 8 (5) :609-617.

[15]KZHYSHKOWSKA J, KRUSELL L.Cross-talk between endocytic clearance and secretion in macrophages[J].Immunobiology, 2009, 214 (7) :576-593.

[16]KZHYSHKOWSKA J, WORKMAN G, CARDO-VILA M, et al.Novel function of alternatively activated macrophages:stabilin-1-mediated clearance of SPARC[J].J Immunol, 2006, 176 (10) :5825-5832.

[17]NAGARAJU GP, DONTULA R, EL-RAYES BF, et al.Molecular mechanisms underlying the divergent roles of SPARC in human carcinogenesis[J].Carcinogenesis, 2014, 35 (5) :967-973.

[18]HUNG JY, YEN MC, JIAN SF, et al.Secreted protein acidic and rich in cysteine (SPARC) induces cell migration and epithelial mesenchymal transition through WNK1/snail in non-small cell lung cancer[J].Oncotarget, 2017, 8 (38) :63691-63702.

[19]CHEN Y, ZHANG Y, TAN Y, et al.Clinical significance of SPARC in esophageal squamous cell carcinoma[J].Biochem Biophys Res Commun, 2017, 492 (2) :184-191.

[20]KIM NI, KIM GE, LEE JS, et al.In phyllodes tumors of the breast expression of SPARC (osteonectin/BM40) mRNA by in situ hybridization correlates with protein expression by immunohistochemistry and is associated with tumor progression[J].Virchows Arch, 2017, 470 (1) :91-98.

[21]SALVATIERRA E, ALVAREZ MJ, LEISHMAN CC, et al.SPARC controls melanoma cell plasticity through Rac1[J].PLo S One, 2015, 10 (8) :e0134714.

[22]LIU H, XU Y, CHEN Y, et al.RNA interference against SPARC promotes the growth of U-87MG human malignant glioma cells[J].Oncol Lett, 2011, 2 (5) :985-990.

[23]ALAM R, SCHULTZ CR, GOLEMBIESKI WA, et al.PTEN suppresses SPARC-induced p MAPKAPK2 and inhibits SPARC-induced Ser78 HSP27 phosphorylation in glioma[J].Neuro Oncol, 2013, 15 (4) :451-461.

[24]LEE KS, BAE WK, BAE HG, et al.The fate of traumatic subdural hygroma in serial computed tomographic scans[J].J Korean Med Sci, 2000, 15 (5) :560-568.

[25]LI Z, LI AD, XU L, et al.SPARC expression in gastric cancer predicts poor prognosis:results from a clinical cohort, pooled analysis and GSEA assay[J].Oncotarget, 2016, 7 (43) :70211-70222.

[26]SHI D, JIANG K, FU Y, et al.Overexpression of SPARC correlates with poor prognosis in patients with cervical carcinoma and regulates cancer cell epithelial-mesenchymal transition[J].Oncol Lett, 2016, 11 (5) :3251-3258.

[27]LE BAIL B, FAOUZI S, BOUSSARIE L, et al.Osteonectin/SPARC is overexpressed in human hepatocellular carcinoma[J].J Pathol, 1999, 189 (1) :46-52.

[28]SHIN M, MIZOKAMI A, KIM J, et al.Exogenous SPARC suppresses proliferation and migration of prostate cancer by interacting with integrin beta1[J].Prostate, 2013, 73 (11) :1159-1170.

[29]CHLENSKI A, DOBRATIC M, SALWEN HR, et al.Secreted protein acidic and rich in cysteine (SPARC) induces lipotoxicity in neuroblastoma by regulating transport of albumin complexed with fatty acids[J].Oncotarget, 2016, 7 (47) :77696-77706.

[30]LIU YP, HSIAO M.Exercise-induced SPARC prevents tumorigenesis of colon cancer[J].Gut, 2013, 62 (6) :810-811.

[31]RAHMAN M, CHAN AP, TANG M, et al.A peptide of SPARC interferes with the interaction between caspase8 and Bcl2 to resensitize chemoresistant tumors and enhance their regression in vivo[J].PLo S One, 2011, 6 (11) :e26390.

[32]CHEW A, SALAMA P, ROBBSHAW A, et al.SPARC, FOXP3, CD8and CD45 correlation with disease recurrence and long-term diseasefree survival in colorectal cancer[J].PLo S One, 2011, 6 (7) :e22047.

[33]LIANG JF, WANG HK, XIAO H, et al.Relationship and prognostic significance of SPARC and VEGF protein expression in colon cancer[J].J Exp Clin Cancer Res, 2010, 29:71.

[34]YU XZ, GUO ZY, DI Y, et al.The relationship between SPARC expression in primary tumor and metastatic lymph node of resected pancreatic cancer patients and patients'survival[J].Hepatobiliary Pancreat Dis Int, 2017, 16 (1) :104-109.

[35]JU MJ, QIU SJ, FAN J, et al.Peritumoral activated hepatic stellate cells predict poor clinical outcome in hepatocellular carcinoma after curative resection[J].Am J Clin Pathol, 2009, 131 (4) :498-510.

[36]NAKATANI K, SEKI S, KAWADA N, et al.Expression of SPARC by activated hepatic stellate cells and its correlation with the stages of fibrogenesis in human chronic hepatitis[J].Virchows Arch, 2002, 441 (5) :466-474.

[37]LIN ZY, CHUANG WL.Genes responsible for the characteristics of primary cultured invasive phenotype hepatocellular carcinoma cells[J].Biomed Pharmacother, 2012, 66 (6) :454-458.

[38]DENG B, QU L, LI J, et al.MiRNA-211 suppresses cell proliferation, migration and invasion by targeting SPARC in human hepatocellular carcinoma[J].Sci Rep, 2016, 6:26679.

[39]ANG C, MIURA JT, GAMBLIN TC, et al.Comprehensive multiplatform biomarker analysis of 350 hepatocellular carcinomas identifies potential novel therapeutic options[J].J Surg Oncol, 2016, 113 (1) :55-61.

[40]LAU CP, POON RT, CHEUNG ST, et al.SPARC and Hevin expression correlate with tumour angiogenesis in hepatocellular carcinoma[J].J Pathol, 2006, 210 (4) :459-468.

[41]ZHU XC, DONG QZ, ZHANG XF, et al.microRNA-29a suppresses cell proliferation by targeting SPARC in hepatocellular carcinoma[J].Int J Mol Med, 2012, 30 (6) :1321-1326.

[42]ZHANG Y, YANG B, DU Z, et al.Aberrant methylation of SPARC in human hepatocellular carcinoma and its clinical implication[J].World J Gastroenterol, 2012, 18 (17) :2043-2052.

[43]WAN J, WEN D, DONG L, et al.Establishment of monoclonal HCC cell lines with organ site-specific tropisms[J].BMC Cancer, 2015, 15:678.

[44]ATORRASAGASTI C, MALVICINI M, AQUINO JB, et al.Overexpression of SPARC obliterates the in vivo tumorigenicity of human hepatocellular carcinoma cells[J].Int J Cancer, 2010, 126 (11) :2726-2740.

[45]HUA HW, JIANG F, HUANG Q, et al.Re-sensitization of 5-FU resistance by SPARC through negative regulation of glucose metabolism in hepatocellular carcinoma[J].Tumour Biol, 2015, 36 (1) :303-313.

施引文献

资源附件(0)

访问统计